#South Korea #Seoul #Seegene #CURECA #STAgora

Seegene Unveils Groundbreaking Technologies at ADLM 2025

On August 11, 2025, during the ADLM 2025 conference held in Chicago, Seegene Inc., a global leader in molecular diagnostics, unveiled two cutting-edge technologies that promise to reshape lab automation and infectious disease monitoring. The technologies include CURECA™, the world’s first fully unattended PCR automation system, and STAgora™, a real-time global diagnostics data analysis platform. Both innovations aim to enhance laboratory automation and improve data utilization in the battle against infectious diseases.

Advancing Molecular Diagnostics

Dr. Jong-Yoon Chun, the CEO and Chairman of Seegene, emphasized during the July 30 press conference the critical importance of these technologies. He stated, “With CURECA™ and STAgora™, we are taking a significant step forward in the future of diagnostics. Our goal is to enable labs around the world to automate complex testing workflows and to utilize diagnostic data more effectively, which will aid global efforts towards a world free from diseases.”

Currently, many molecular diagnostic systems rely heavily on qualified personnel for repetitive manual tasks. This limits both efficiency and scalability. CURECA™ aims to address these limitations by being the first industry system designed to fully automate every stage of the PCR testing process, including traditionally manual pre-treatment steps. Seegene stresses that complete automation of diagnostics requires three key factors: operation without highly skilled professionals, continuous 24/7 processing, and uninterrupted sample input—criteria that CURECA™ fulfills.

One of CURECA™’s dedicated modules, known as CURECA™ Prep, is capable of processing a diverse range of sample types, such as urine, blood, sputum, and stool. This addresses one of the longstanding challenges in laboratory automation by enabling the system to handle various sample preparations without manual operation.

Comprehensive Workflow Automation

The entire PCR workflow—from sample loading to results analysis, nucleic acid extraction, and amplification—is automated, significantly reducing human error while enhancing workflow efficiency. By automating diagnostics, labs can redeploy qualified staff to higher-value tasks, streamlining processes that traditionally involved manual labor.

Automation in diagnostics has historically faced challenges due to the variability of samples and dependence on trained staff for repetitive pre-treatment tasks. CURECA™ helps labs overcome such constraints by providing a scalable, adaptable system that can be tailored for various laboratory sizes and workflows. The CURECA™ Prep module also has the potential to extend its applications to clinical chemistry and immunodiagnostics as Seegene explores broader automation solutions.

Transforming Data into Actionable Insights

In conjunction with CURECA™, Seegene also introduced STAgora™, a new platform designed to collect and analyze PCR testing data in real time. This platform provides laboratories with a contextual foundation to enhance diagnostic workflows and includes over 40 analytical tools for infection trend tracking, positivity monitoring at hospital levels, and analyzing co-infection patterns involving multiple pathogens.

Rather than functioning solely as a data repository, STAgora™ is designed as an integrated platform that helps labs draw meaningful aggregated insights from their testing data. Currently, individual test results often offer limited insights without broader reference points. STAgora™ seeks to correct this issue by allowing hospitals to generate their own statistical datasets and compare aggregated data across institutions, thus enabling faster detection of infection patterns and supporting better-informed decision-making.

Committing to a Disease-Free Future

Dr. Chun reiterated Seegene's long-term vision of creating “a world without diseases,” noting that the introduction of CURECA™ and STAgora™ complements the company's five core technological pillars, including Seegene's proprietary PCR technology, the Seegene Digitalized Development System (SGDDS) for automated test development, and a global technology-sharing initiative.

Industry experts at ADLM 2025 expressed strong interest in Seegene’s innovative technologies. Jamel Giuma, CEO of Miami-based JTG Consulting Group, remarked, “I have attended many ADLM conferences over the years, and CURECA™ is one of the most innovative solutions I have seen so far. I believe in its potential to simplify laboratory workflows, reduce laboratory staff workload, and significantly enhance overall operational efficiency.”

Dr. Chun concluded, “With CURECA™ and STAgora™, we are addressing long-standing barriers in molecular diagnostics. Just as smartphones and electric vehicles transformed their industries, we believe these technologies will redefine the field of diagnostics, helping laboratories achieve true automation and fully leverage diagnostic data.